NCT04543071 - Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

June 30, 2028

Study Completion Date

August 31, 2028

Conditions

Pancreatic CancerAdenocarcinoma of the PancreasAdenocarcinoma

Interventions

DRUG

Motixafortide

1.25 mg/kg subcutaneous (SC) monotherapy daily for 5 days during priming, followed by twice weekly

DRUG

Cemiplimab

350 mg intravenous (IV) once every 21 days

DRUG

Gemcitabine

1000 mg/m2 IV on days days 1, 8, 14 (every 28 days)

DRUG

Nab paclitaxel

125 mg/m2 IV on days 1, 8, 14 (every 28 days)

Trial Locations (3)

RECRUITING

Columbia University Irving Medical Center, New York

RECRUITING

Medical College of Wisconsin, Wisconsin Diagnostic Labratories, Milwaukee

RECRUITING

Brown University, Providence